Report Preview

The global advanced drug delivery systems market size was valued at USD 52.28 billion in 2021 and is projected to reach up to USD 145.0 billion in 2028, exhibiting a CAGR of 16.1% in the forecast period. The increase in the number of the chronic diseases within the geriatric population of the developing similarly because the developed nations are driving the market growth. For instance, the number of patients with cardiovascular diseases (CVDs) approximately doubled from 271 million in 1990 to 523 million in 2019. The rising prevalence of such diseases can be accredited to the adoption of unhealthy and sedentary lifestyles, rising geriatric population, excessive consumption of saturated trans-fat food, tobacco consumption, physical inactivity, obesity, and family history of CVDs. As per a study, in 2019, around 28.2 million adults in the US were detected with heart diseases. The market is growing in a steady pace and there is a rise in the healthcare expenditure in the emerging nations.

Type Insights

On the basis of the type, the oral drug delivery system market is predicted to possess the largest market share throughout the forecast period. The oral drug delivery phase is predicted to dominate the market within the forthcoming years because of a rise within the quality of this delivery system. within the recent years there has been a rise within the quality of this technique creative person most well-liked by the patients in addition because the physicians.

The oral drug delivery method is the most common and chosen drug administration route by the physicians and the patients. The demand for this route of administration mostly relies in the convenience of intake and the availability of a broad window of the therapeutic index, which, in turn, lowers the probability of toxicity and side effects. The augmented pace of advanced oral drug delivery system development is raised by an increasing market of controlled release formulations and new launches in key therapeutic areas such as the metabolic, central nervous system and cardiovascular, and respiratory diseases. For instance, in 2020, Progenity Inc. stated positive preliminary preclinical data about the performance of its oral drug delivery system (DDS), the DDS capsule that uses a proprietary autonomous localization technology intended to identify the ileal/ileocecal region of the GI tract. This expertise is based on anatomy and is intended to resist inconsistency in physiological conditions like motility, pH, and bacteria. The launch of such products will provide growth opportunities for the segment in the near future.

Product Type Insights

On the basis of product type, the nanocarrier phase is predicted to grow well throughout the forecast. As this kind of drug are often administered within the oral means or it can even be used for inhalation in addition as application. it’s extraordinarily helpful for the targeted delivery of the medicine. the utilization of a nanocarrier helps in rising the potency of the intake of a drug because it in an exceedingly position to focus on the positioning of the affected space in lot of economical means. It conjointly helps Cindy absorption of the medicine in a very fascinating means particularly for the medicine that are poorly soluble.

In the recent years, constant analysis on developing nanocarrier has accrued the quantity of the nanocarrier. it’s wide used for the patients suffering with cancer. the utilization of nanocarrier for the drug delivery within the patients suffering with cancer has proved to be extraordinarily economical in delivering the medicine to the desired website. It provides higher therapeutic outputs. so as to treat differing types of tumors an oversized variety of nanocarrier product are approved by the restrictive bodies.

End User Insights

On the basis of the end user, the hospital segment will lead the market during the forecast period. The hospital segment is anticipated to grow at a significant CAGR during the forecast period. As it has been an increase in the use of advanced drug delivery for treating different orthopaedic conditions, oncology and neurology the market is anticipated to grow. The convenience of advanced infrastructure add professionals with great expertise in this field will drive the market during the forecast period. The increased number of chronic diseases in the elderly population is anticipated to grow in the coming years and it will drive the market growth.

Region Insights

The North American region is anticipated to rule the market during the forecast period. The convenience of advanced health care facilities and a growing popularity of the advanced drug delivery in the region will boost the market growth during the forecast period. The region has dominated the market in the past due to the availability of various solutions. Since there has been a great demand for treating numerous chronic diseases with the use of the drugs in the self- administered form the market is predicted to grow. The use of injectable is expected to grow during the forecast period.

Moreover, the joint initiatives taken by the non-profit organizations, market players, and government agencies are also forcing the growth of the market in the region. For example, in March 2022, TFF Pharmaceuticals, Inc. entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), which is a part of the United States Army Medical Research and Development Command and the United States Army’s foremost institution and facility for protective measures against biological warfare, and the Geneva Foundation that improves innovative medical research within the United States military. Such joint initiatives are also estimated to propel the growth of the market. Thus, owing to the aforementioned factors, the North American region is projected to show growth over the forecast period.

Key Companies Insights

Key players are focusing on their technological partnerships, collaborations, and merger & acquisitions strategies to gain a competitive edge and expand their product portfolio & business footprint. The ongoing Covid-19 pandemic hampered the systems across the globe and drove market players to innovate products for several opportunities. Some of the key players operating in the global advanced drug delivery systems market include:

• Baxter
• Boston Scientific Corporation
• AbbVie Inc.
• Becton, Dickinson and Company
• Kindeva Drug Delivery L.P
• Bausch Health Companies Inc.
• Novo Nordisk A/S
• Ocular Therapeutix, Inc.
• 3M
• Raphas Co., Ltd.
• GALDERMA
• NanoPass
• Altaris
• MicropointTechnologies
• Takeda Pharmaceutical Company Limited
• Other players

Some of the Recent Developments:

• In March 2022, Corium, Inc. received United States Food and Drug Administration (FDA) approval for Corium’s ADLARITY (donepezil transdermal system) for the treatment of patients with mild, moderate, or severe dementia of the Alzheimer’s type.
• In March 2022, the United States Food and Drug Administration approved the first generic of Symbicort Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients of six years of age and older, and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
• In February 2019, Sandoz, a Novartis division, received European Commission authorization in Spain for its adalimumab biosimilar, HYRIMOZ, for subcutaneous injection in a syringe or a prefilled pen.

Segments

By Type

• Oral
• Inhalation
• Carrier
• Injection
• Targeted
• Others

By Product Type

• Nanocarriers
• Micro Needle Patch
• Hydrogel
• Drug Eluting Lens

By End User

• Hospitals
• Specialized clinics
• Others

By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt